Anti-inflammatory activity of BCM-95 (bio-enhanced formulation of turmeric with increased bioavailabilty) compared to Curcumin in Wistar rats

Sayeli Vinaykumar, Urval Pundarik Rathnakar, Ullal Sheetal Dinkar, Kamath Priyanka, Tiwary Gaurav, Ashok Shenoy Kudgi, Revappala Sekhar Nishith

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objective: To evaluate anti-inflammatory activity of bioenhanced turmeric formulation (BCM-95) compared to commercial Curcumin formulation (Curcuminoids 95%) in Carrageenan-induced acute inflammatory model. Materials and Methods: Thirty six Wistar rats were divided into six groups-Normal control (2 ml of vehicle), Standard control (Indomethacin 10 mg/kg), 2 doses of BCM 95 (10 and 20 mg/kg) and Curcuminoids 95% (10 and 20 mg/kg). Paw volume was measured using a digital plethysmometer. Vehicle or test drugs were given to rats 30 min before carrageenan administration. Baseline paw volume reading (V0) was noted just prior to administration of 0.1 ml of 1% carrageenan to right hind paw of the rat. Test paw volume readings (Vt) were measured at 30, 60, 120, 180, 240, 300 and 360 min, after carrageenan injection. Oedema expressed as increased paw volume (vt-v0) was noted and percentage inhibition of oedema was calculated for all treatment groups. Statistical analysis: Difference between groups were analyzed with ANOVA followed by Tukey test. Results: All treatment groups demonstrated significant (p<0.05) anti-inflammatory activity (oedema suppression) compared to normal control. Anti-inflammatory activity of BCM 95 treated groups were comparable to standard control group except at certain time points, whereas the same activity at all-time points with Curcuminoid 95% treated groups were significantly less than standard control group. Percentage inhibition of paw oedema was maximum with standard control group followed by BCM 95 treated groups followed by Curcuminoid 95% treated groups. Conclusion: BCM 95 treated groups showed significant anti-inflammatory activity compared to Curcuminoid 95% treated groups.

Original languageEnglish
Pages (from-to)380-384
Number of pages5
JournalPharmacognosy Journal
Volume8
Issue number4
DOIs
Publication statusPublished - 01-01-2016
Externally publishedYes

Fingerprint

Curcuma
Curcumin
Carrageenan
Wistar Rats
Edema
Anti-Inflammatory Agents
Control Groups
Reading
Indomethacin
Analysis of Variance
Injections
Therapeutics
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Drug Discovery

Cite this

Vinaykumar, S., Rathnakar, U. P., Dinkar, U. S., Priyanka, K., Gaurav, T., Kudgi, A. S., & Nishith, R. S. (2016). Anti-inflammatory activity of BCM-95 (bio-enhanced formulation of turmeric with increased bioavailabilty) compared to Curcumin in Wistar rats. Pharmacognosy Journal, 8(4), 380-384. https://doi.org/10.5530/pj.2016.4.11
Vinaykumar, Sayeli ; Rathnakar, Urval Pundarik ; Dinkar, Ullal Sheetal ; Priyanka, Kamath ; Gaurav, Tiwary ; Kudgi, Ashok Shenoy ; Nishith, Revappala Sekhar. / Anti-inflammatory activity of BCM-95 (bio-enhanced formulation of turmeric with increased bioavailabilty) compared to Curcumin in Wistar rats. In: Pharmacognosy Journal. 2016 ; Vol. 8, No. 4. pp. 380-384.
@article{a337b754cd35484da7cbe9beb371b1a9,
title = "Anti-inflammatory activity of BCM-95 (bio-enhanced formulation of turmeric with increased bioavailabilty) compared to Curcumin in Wistar rats",
abstract = "Objective: To evaluate anti-inflammatory activity of bioenhanced turmeric formulation (BCM-95) compared to commercial Curcumin formulation (Curcuminoids 95{\%}) in Carrageenan-induced acute inflammatory model. Materials and Methods: Thirty six Wistar rats were divided into six groups-Normal control (2 ml of vehicle), Standard control (Indomethacin 10 mg/kg), 2 doses of BCM 95 (10 and 20 mg/kg) and Curcuminoids 95{\%} (10 and 20 mg/kg). Paw volume was measured using a digital plethysmometer. Vehicle or test drugs were given to rats 30 min before carrageenan administration. Baseline paw volume reading (V0) was noted just prior to administration of 0.1 ml of 1{\%} carrageenan to right hind paw of the rat. Test paw volume readings (Vt) were measured at 30, 60, 120, 180, 240, 300 and 360 min, after carrageenan injection. Oedema expressed as increased paw volume (vt-v0) was noted and percentage inhibition of oedema was calculated for all treatment groups. Statistical analysis: Difference between groups were analyzed with ANOVA followed by Tukey test. Results: All treatment groups demonstrated significant (p<0.05) anti-inflammatory activity (oedema suppression) compared to normal control. Anti-inflammatory activity of BCM 95 treated groups were comparable to standard control group except at certain time points, whereas the same activity at all-time points with Curcuminoid 95{\%} treated groups were significantly less than standard control group. Percentage inhibition of paw oedema was maximum with standard control group followed by BCM 95 treated groups followed by Curcuminoid 95{\%} treated groups. Conclusion: BCM 95 treated groups showed significant anti-inflammatory activity compared to Curcuminoid 95{\%} treated groups.",
author = "Sayeli Vinaykumar and Rathnakar, {Urval Pundarik} and Dinkar, {Ullal Sheetal} and Kamath Priyanka and Tiwary Gaurav and Kudgi, {Ashok Shenoy} and Nishith, {Revappala Sekhar}",
year = "2016",
month = "1",
day = "1",
doi = "10.5530/pj.2016.4.11",
language = "English",
volume = "8",
pages = "380--384",
journal = "Pharmacognosy Journal",
issn = "0975-3575",
publisher = "Pharmacognosy Network Worldwide",
number = "4",

}

Anti-inflammatory activity of BCM-95 (bio-enhanced formulation of turmeric with increased bioavailabilty) compared to Curcumin in Wistar rats. / Vinaykumar, Sayeli; Rathnakar, Urval Pundarik; Dinkar, Ullal Sheetal; Priyanka, Kamath; Gaurav, Tiwary; Kudgi, Ashok Shenoy; Nishith, Revappala Sekhar.

In: Pharmacognosy Journal, Vol. 8, No. 4, 01.01.2016, p. 380-384.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Anti-inflammatory activity of BCM-95 (bio-enhanced formulation of turmeric with increased bioavailabilty) compared to Curcumin in Wistar rats

AU - Vinaykumar, Sayeli

AU - Rathnakar, Urval Pundarik

AU - Dinkar, Ullal Sheetal

AU - Priyanka, Kamath

AU - Gaurav, Tiwary

AU - Kudgi, Ashok Shenoy

AU - Nishith, Revappala Sekhar

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective: To evaluate anti-inflammatory activity of bioenhanced turmeric formulation (BCM-95) compared to commercial Curcumin formulation (Curcuminoids 95%) in Carrageenan-induced acute inflammatory model. Materials and Methods: Thirty six Wistar rats were divided into six groups-Normal control (2 ml of vehicle), Standard control (Indomethacin 10 mg/kg), 2 doses of BCM 95 (10 and 20 mg/kg) and Curcuminoids 95% (10 and 20 mg/kg). Paw volume was measured using a digital plethysmometer. Vehicle or test drugs were given to rats 30 min before carrageenan administration. Baseline paw volume reading (V0) was noted just prior to administration of 0.1 ml of 1% carrageenan to right hind paw of the rat. Test paw volume readings (Vt) were measured at 30, 60, 120, 180, 240, 300 and 360 min, after carrageenan injection. Oedema expressed as increased paw volume (vt-v0) was noted and percentage inhibition of oedema was calculated for all treatment groups. Statistical analysis: Difference between groups were analyzed with ANOVA followed by Tukey test. Results: All treatment groups demonstrated significant (p<0.05) anti-inflammatory activity (oedema suppression) compared to normal control. Anti-inflammatory activity of BCM 95 treated groups were comparable to standard control group except at certain time points, whereas the same activity at all-time points with Curcuminoid 95% treated groups were significantly less than standard control group. Percentage inhibition of paw oedema was maximum with standard control group followed by BCM 95 treated groups followed by Curcuminoid 95% treated groups. Conclusion: BCM 95 treated groups showed significant anti-inflammatory activity compared to Curcuminoid 95% treated groups.

AB - Objective: To evaluate anti-inflammatory activity of bioenhanced turmeric formulation (BCM-95) compared to commercial Curcumin formulation (Curcuminoids 95%) in Carrageenan-induced acute inflammatory model. Materials and Methods: Thirty six Wistar rats were divided into six groups-Normal control (2 ml of vehicle), Standard control (Indomethacin 10 mg/kg), 2 doses of BCM 95 (10 and 20 mg/kg) and Curcuminoids 95% (10 and 20 mg/kg). Paw volume was measured using a digital plethysmometer. Vehicle or test drugs were given to rats 30 min before carrageenan administration. Baseline paw volume reading (V0) was noted just prior to administration of 0.1 ml of 1% carrageenan to right hind paw of the rat. Test paw volume readings (Vt) were measured at 30, 60, 120, 180, 240, 300 and 360 min, after carrageenan injection. Oedema expressed as increased paw volume (vt-v0) was noted and percentage inhibition of oedema was calculated for all treatment groups. Statistical analysis: Difference between groups were analyzed with ANOVA followed by Tukey test. Results: All treatment groups demonstrated significant (p<0.05) anti-inflammatory activity (oedema suppression) compared to normal control. Anti-inflammatory activity of BCM 95 treated groups were comparable to standard control group except at certain time points, whereas the same activity at all-time points with Curcuminoid 95% treated groups were significantly less than standard control group. Percentage inhibition of paw oedema was maximum with standard control group followed by BCM 95 treated groups followed by Curcuminoid 95% treated groups. Conclusion: BCM 95 treated groups showed significant anti-inflammatory activity compared to Curcuminoid 95% treated groups.

UR - http://www.scopus.com/inward/record.url?scp=85009367041&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85009367041&partnerID=8YFLogxK

U2 - 10.5530/pj.2016.4.11

DO - 10.5530/pj.2016.4.11

M3 - Article

VL - 8

SP - 380

EP - 384

JO - Pharmacognosy Journal

JF - Pharmacognosy Journal

SN - 0975-3575

IS - 4

ER -